Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Recommendation To Ban Irrational Drugs – Science Prevails But Calls To Go The Whole Hog

Executive Summary

An Indian expert panel has recommended prohibiting over 300 "irrational" fixed dose combinations, reinforcing a previous ban on such products. Some stakeholders want such weeding out to be an ongoing exercise alongside fool-proofing the regulatory system.

You may also be interested in...

Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India

Novartis’s plans for triple drug diabetes combination which includes vildagliptin have been turned down in India at least for now, with an expert panel questioning the rationale of such therapy.

India's 'Haphazard' Ban On 344 Combos Struck Down But Will Science Prevail?

An Indian court has struck down a controversial government order aimed at weeding out over 300 irrational fixed dose combinations, bringing some relief to the pharma industry, although the case seems far from over. The jury appears to be still out on the therapeutic rationale of some of the combinations, raising questions around patient interests.

India asks states to cancel licences for unauthorised fixed dose combinations

India's health ministry is clamping down on the country's burgeoning and increasingly confusing market for fixed dose combination drugs, limiting the tendency for manufacturers to formulate approved drugs in seemingly irrational combinations. The ministry is making it clear that the Drugs Controller General of India must have approved as 'new drugs' not only the components of combinations but also the combinations themselves.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts